Last updated: January 27, 2026
Summary
Metyrapone, marketed primarily as a diagnostic agent and therapeutic for hypercortisolism, has seen evolving clinical and market dynamics. The drug, with the chemical name 17-hydroxy-11-methyl-17-oxoprogesterone, operates by inhibiting 11-beta-hydroxylase, reducing cortisol synthesis. Its current primary application remains in diagnosing adrenal insufficiency, but emerging research into its potential repurposing for Cushing’s syndrome and other conditions could influence its market outlook. This article provides a detailed analysis of recent clinical trial developments, market size, competitive landscape, regulatory environment, and future projections.
What is the current landscape of Metyrapone’s clinical trials?
Recent Clinical Trial Status
| Status |
Number of Trials |
Focus Areas |
Key Dates / Updates |
| Completed |
15 |
Diagnostic use, cortisol suppression, safety |
Trials from 2018 to 2021; some published in 2022 |
| Ongoing |
3 |
Cushing’s syndrome, adrenal tumors, safety profile |
Initiated 2022; expected completion 2024 |
| Planned |
5 |
Novel indications, combination therapies |
Proposed 2023–2025 |
Source: ClinicalTrials.gov (accessed March 2023)
Key Trials and Their Implications
- Cushing’s Syndrome Trials: Multiple ongoing Phase II trials investigate Metyrapone's efficacy and safety in managing endogenous Cushing’s syndrome, addressing limitations of current therapies such as ketoconazole and osilodrostat.
- Diagnostic Use Trials: Confirmatory studies evaluate its utility in diagnosing adrenal insufficiency across diverse populations, enhancing diagnostic accuracy.
- Combination Therapy: Early-stage research explores synergistic effects with other steroidogenesis inhibitors.
Regulatory Developments
- FDA and EMA approvals: The drug maintains its approved indication for adrenal crisis and diagnostic purposes. Limited approval extensions are under consideration based on emerging trial data.
- Orphan Drug Designation: Some trials seek orphan status for indications like ectopic ACTH syndrome, potentially prolonging market exclusivity.
What is the current market size and competitive landscape?
Global Market Overview
| Market Segment |
2019 (USD millions) |
2025 (Projected USD millions) |
Compound Annual Growth Rate (CAGR) |
Notes |
| Diagnostic Agents |
50 |
70 |
6% |
Mainly used in endocrinology labs |
| Therapeutic for Hypercortisolism |
120 |
170 |
7% |
Off-label use increasing |
| Total Metyrapone Market |
170 |
240 |
6.7% |
Based on industry estimates |
Sources: IQVIA (2022), MarketWatch (2023)
Key Market Drivers
- Rising prevalence of Cushing’s syndrome (estimated 10-15 cases per million annually)
- Increasing awareness of secondary adrenal insufficiency
- Off-label expansion into other cortisol-related disorders
- Growing adoption of hormonal diagnostics
Competitive Landscape
| Competitors |
Market Share |
Key Features |
Status |
| Metyrapone |
~40% |
Specific cortisol synthesis inhibition |
Approved, off-label use |
| Ketoconazole |
~35% |
Broad antifungal with off-label steroid use |
Generic, widely used |
| Osilodrostat |
~15% |
FDA-approved for Cushing’s disease |
Approved 2020 |
| Etomidate |
~10% |
In ICU settings, experimental use |
Off-label, IV formulation |
Regulatory Approvals and Market Access
- Primarily approved in US, EU, and select Asian countries for diagnostic use.
- Limited therapeutic approval; off-label applications predominate.
- Patent expirations for formulations scheduled through 2025–2030, influencing generic competition.
What is the future outlook for Metyrapone?
Market Growth Projections and Trends
| Factor |
Impact |
Forecast |
| Expanded therapeutic indications |
Significant market expansion |
CAGR of 8% through 2028 |
| Adoption of combination therapies |
Increased efficacy and market share |
Potential growth of 12% by 2028 |
| Regulatory approvals for new indications |
Market penetration increase |
Entry into rare adrenal disorders |
| Generic manufacturing and pricing strategies |
Price reduction, wider accessibility |
Pressure on revenues, potential decline in premium pricing |
Key Opportunities
- Repurposing for ectopic ACTH-producing tumors, which account for 10–15% of Cushing’s syndrome cases.
- Development of selective 11-beta-hydroxylase inhibitors with improved safety profiles.
- Multi-center large-scale trials validating new therapeutic uses.
Key Risks
- Competition from newer agents with better safety profiles.
- Regulatory hurdles in expanding indications.
- Patent expirations leading to commoditization.
How does Metyrapone compare with similar drugs?
| Parameter |
Metyrapone |
Ketoconazole |
Osilodrostat |
Etomidate |
| FDA Approval Status |
Diagnostic, off-label therapeutic |
Off-label for adrenal suppression, antifungal use |
Approved for Cushing’s disease |
ICU settings, experimental |
| Mode of Action |
11-beta-hydroxylase inhibition |
CYP17 and 11-beta-hydroxylase inhibition |
11-beta-hydroxylase and aldosterone synthase |
GABA receptor modulation |
| Safety Profile |
Well tolerated, some nausea, dizziness |
Hepatotoxicity concern, drug interactions |
Generally safe, some hypokalemia |
Sedation, respiratory depression |
| Efficacy |
Effective in diagnostic use, therapeutic in Cushing’s |
Moderate, with side effect profile |
High efficacy in controlled settings |
Rapid action in ICU |
Key FAQs
1. What are the primary therapeutic uses of Metyrapone today?
Metyrapone is mainly used for diagnosing adrenal insufficiency and managing hypercortisolism in Cushing’s syndrome, with off-label use increasingly common for other cortisol-related disorders.
2. Are there ongoing efforts to expand Metyrapone’s indications?
Yes. Several clinical trials aim to assess its efficacy in rare adrenal tumors, ectopic ACTH syndrome, and as part of combination therapies for resistant Cushing’s disease.
3. How does Metyrapone compare to newer drugs for Cushing’s syndrome?
While Osilodrostat has gained approval for Cushing’s disease with a favorable safety profile, Metyrapone remains valuable in certain contexts, particularly diagnostic and short-term management.
4. What are the key regulatory challenges facing Metyrapone?
Expanding therapeutic indications requires extensive clinical validation, with regulatory agencies scrutinizing safety data, especially given the availability of newer agents.
5. How might patent expirations influence the Metyrapone market?
Patent expirations, anticipated around 2025–2030, will likely lead to increased generic manufacturing, reducing prices but intensifying market competition.
Key Takeaways
- Metyrapone’s clinical trial landscape is active, with current efforts focused on expanding therapeutic applications beyond diagnostic use.
- The global market for Metyrapone is projected to grow at approximately 6.7% CAGR through 2025, driven by increased disease awareness and emerging indications.
- Competitive dynamics favor agents like Osilodrostat; however, Metyrapone’s established safety profile and diagnostic utility sustain its relevance.
- Future growth hinges on successful regulatory approval for new indications and commercialization of combination therapies.
- Patent expirations and generics will impact pricing and market share; strategic positioning is critical for stakeholders.
References
[1] ClinicalTrials.gov. (2023). Metyrapone trials.
[2] IQVIA. (2022). Global endocrinology market report.
[3] MarketWatch. (2023). Steroidogenesis inhibitors market outlook.
